Innova Captab
683.15
-2.10(-0.31%)
Market Cap₹3,909.32 Cr
PE Ratio29.68
IndustryHealthcare
Company Performance:
1D-0.31%
1M+0.48%
6M-18.21%
1Y-18.11%
5Y+26.18%
View Company Insightsright
More news about Innova Captab
16Jan 26
Innova Captab Limited Schedules Board Meeting for Q3FY26 Results and Interim Dividend Consideration
Innova Captab Limited has scheduled a board meeting for January 23, 2026, to consider Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025, and evaluate an interim dividend proposal for FY2025-26. The record date for potential dividend eligibility is set for January 30, 2026, with the trading window closed since January 1, 2026, and reopening 48 hours after results declaration in compliance with SEBI insider trading regulations.
 no imag found
07Nov 25
Innova Captab Targets 25% Revenue Growth with ₹300 Crore Capex Plan Amid Strong Q2 Performance
Innova Captab Limited has announced a growth strategy targeting a 25% revenue increase through CDMO business expansion and entry into regulated markets. The company plans to invest ₹300 crore in capital expenditure for capacity addition and R&D. Q2 FY26 financial results show 19.50% YoY revenue growth to ₹380.40 crore, 8% EBITDA growth to ₹56.10 crore, and PAT of ₹29.70 crore. The company's strategy includes strengthening API production, scaling up formulation exports, expanding oncology portfolio, and enhancing margins through vertical integration and global partnerships. Recent regulatory inspections of facilities in Baddi and Jammu reinforce the company's adherence to global quality standards.
 no imag found
20Oct 25
Innova Captab's Jammu Facility Poised for GMP Compliance Certificate from Ukraine Drug Authority
Innova Captab Limited's manufacturing facility in Jammu has received a recommendation for Good Manufacturing Practice (GMP) compliance certification from the State Service of Ukraine on Medicines and Drugs Control (SMDC). The SMDC, a participating authority under the Pharmaceutical Inspection Co-operation Scheme (PIC/S), completed a successful inspection of the facility located at SIDCO Industrial Complex, Kathua, Jammu & Kashmir. This recommendation enhances Innova Captab's global credibility, potentially facilitating access to regulated markets and affirming the facility's high manufacturing standards.
 no imag found
16Oct 25
Innova Captab Faces ₹15.81 Crore GST Demand Over Excess Input Tax Credit Refund Claims
Innova Captab Limited received a Show Cause cum Demand Notice from CGST Commissionerate, Shimla, for alleged excess refund claims of Input Tax Credit. The notice covers May 2020 to March 2024, demanding ₹15,81,37,255.40 with additional interest and penalties. The company is accused of incorrectly applying for refunds under Rule 89(4) instead of Rule 89(4B) of CGST Rules. Innova Captab denies merit in the notice and plans to submit a defense within 30 days.
 no imag found
07Aug 25
Innova Captab Reports Robust Q1 Results with 19% Revenue Growth
Innova Captab announced robust Q1 financial results, with revenue increasing 19% YoY to ₹351.50 crore. EBITDA grew 28% to ₹56.60 crore, and PAT rose 5% to ₹31.00 crore. The CDMO Services segment revenue reached ₹249.50 crore, up 8% YoY, while Branded Generics revenue surged 59% to ₹102.10 crore. The company's new Jammu facility gained momentum, contributing to overall growth. Management expressed confidence in sustainable growth and long-term value creation.
 no imag found
19May 25
Innova Captab Reports Strong Q4 Performance with Improved EBITDA and Revenue Growth
Innova Captab's Q4 financial results show significant growth. Revenue increased by 19.77% to 3.15 billion ₹, while EBITDA grew by 25.20% to 477.00 million ₹. The EBITDA margin improved by 65 bps to 15.16%. Net profit saw a modest 3.14% increase to 296.00 million ₹. The company's performance indicates strong market demand and improved operational efficiency.
 no imag found
Innova Captab
683.15
-2.10
(-0.31%)
1 Year Returns:-18.11%
Industry Peers
Sun Pharmaceutical
1,714.60
(-0.20%)
Divis Laboratories
5,882.00
(+0.55%)
Torrent Pharmaceuticals
4,029.20
(-0.55%)
Lupin
2,294.10
(-0.18%)
Dr Reddys Laboratories
1,191.40
(-0.39%)
Cipla
1,215.90
(+1.12%)
Zydus Life Science
891.55
(+2.07%)
Mankind Pharma
2,041.90
(+0.09%)
Aurobindo Pharma
1,335.70
(+0.43%)
Alkem Laboratories
5,246.00
(+1.42%)